new targets to treat acute myeloid leukemia (aml) with flt3 mutations
Published 7 years ago • 686 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
1:42
developments in prognostic factors of acute myeloid leukemia (aml)
-
1:03
targeted therapies in newly diagnosed aml: bcl2, flt3 and idh inhibitors
-
2:25
advances in acute myeloid leukemia (aml) treatment – updating 7 3
-
5:30
treating acute myeloid leukemia with valor – vosaroxin in combination with cytarabine
-
1:19
new treatments for aml
-
0:51
unmet needs in front-line therapy for patients with flt3-mutated aml
-
1:36
targeted therapy for aml
-
6:39
treatment failure and relapse in acute myeloid leukemia (aml)
-
6:47
the 2021 treatment algorithm for flt3-mutated aml
-
8:14
progress in the treatment of tp53 mutated aml
-
0:42
talquetamab treatment in patients with r/r myeloma with prior exposure to t-cell-directed therapies
-
3:37
the future of aml treatment
-
1:21
new drug targets for aml
-
2:02
progress in acute myeloid leukemia treatment – collaborating to develop targeted therapies
-
3:14
flt3 mutations for targeted therapy in aml
-
1:12
the value of flt3 inhibitors in aml and focus for future trial designs
-
1:11
are idh mutations good minimal residual disease (mrd) markers in acute myeloid leukemia (aml)?
-
1:40
the role of menin inhibitors in the treatment of aml
-
3:31
update on quantum-first: quizartinib soc chemotherapy & as continuation therapy in flt3-itd aml
-
2:20
best treatment strategy for flt3 itd aml
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity